BioFlash-logo

BioFlash

Business News >

More Information

Location:

United States

Language:

English


Episodes

Where does drug pricing cross the line into gouging?

1/15/2018
More
Big money was evident throughout the 36th J.P. Morgan Healthcare Conference — from the $200 an hour it costs to meet with someone in some hotel lobbies or lounges to the price of drugs. But as life-changing, one-shot-and-you're-done gene therapies emerge as options — with price tags approaching or exceeding $1 million — how much is too much?

Duration:00:14:54

From full-body scanners to new-age drugs, Mir Imran's passion for 'big, unsolved mysteries'

1/5/2018
More
Mir Imran developed an early defibrillator and those full-body scanners at airport security. After a career that's also included patents for medical devices, his Rani Therapeutics now is taking on new-age drugs designed to reduce side effects and increase efficacy.

Duration:00:39:05

How a venture fund weighs risk and spots scientific passion

1/4/2018
More
Nick Naclerio oversaw many deals by life sciences tools maker Illumina Inc. Now he's heading up a $230 million fund, which takes its name from and includes Illumina as an investor.

Duration:00:23:58

How a startup is using machine learning to speed new Parkinson's, ALS drugs

1/4/2018
More
Alice Zhang sees a way of tapping machine learning to accelerate the development of new drugs to treat Parkinson's disease and other brain diseases — and dismiss the ones that won't work.

Duration:00:22:42

What an emerging drug company is doing to disrupt depression

1/2/2018
More
Dr. Atul Mahableshwarkar, hired last summer by BlackThorn Therapeutics as vice president of clinical development, talks about the South San Francisco drug company's attack on depression.

Duration:00:28:40

How Glenn Close, Billy Crystal and a S.F. nonprofit are conquering the 'last frontier'

10/20/2017
More
Billy Crystal talks about the award he accepted from Bring Change To Mind, the mental health nonprofit cofounded by Glenn Close, while Close talks about eliminating the stigma of mental disorders and changing how mental health issues are discussed, diagnosed and treated.

Duration:00:11:42

No stick: How this East Bay company's FDA win could change diabetics' lives

9/28/2017
More
Jared Watkin, senior vice president of diabetes care for Abbott, talks about the company's recently FDA-approved system to help diabetics monitor glucose without finger sticks.

Duration:00:20:50

Could a Stanford professor's vest help the deaf 'hear' again?

8/28/2017
More
David Eagleman — neuroscientist, New York Times bestselling author, host of an Emmy award-nominated show — believes the brain can be trained to see and hear through patterns of vibration.

Duration:00:20:47

Why this drug company is focusing on rare diseases

8/7/2017
More
Tom Schall, CEO of drug developer ChemoCentryx Inc., talks about the business and patient reasons the company is focused on rare inflammatory and autoimmune diseases.

Duration:00:26:43

What this biotech discovered before, after CEO's death

7/20/2017
More
Dale Schenk was the backbone of Prothena Corp. as the South San Francisco company as it built an impressive portfolio of drugs in a few years, including three that are in four clinical trials today. Then pancreatic cancer killed him. Current Prothena President and CEO Gene Kinney talks about the company and the impact of Schenk's death and life.

Duration:00:27:17

Atul Butte, Big Data and AI don’t want to take your doctor’s job

6/21/2017
More
Atul Butte, the director of the Institute of Computational Health Sciences at the University of California, San Francisco, talks about demystifying machine learning and artificial intelligence and aggregating data to produce more-efficient clinical trials.

Duration:00:17:58

How newborn screening could change the face of health care

6/19/2017
More
Max Bronstein, the chief advocacy and science policy officer at the EveryLife Foundation for Rare Diseases, talks about how increasing newborn screening and developing new screening tests can help patients and drug companies as well as lower the health care bill.

Duration:00:23:36

On eve of biotech's big convention, BIO's boss talks drug prices, 'biosimilars' and Trump

6/18/2017
More
As the Biotechnology Innovation Organization's annual convention gets under way in San Diego, we talk with Jim Greenwood, president and CEO of BIO, about what to expect at this year’s biotech convention, issues with drug pricing and the world according to Trump.

Duration:00:28:37

Genentech's new CEO on 'immune deserts,' drug pricing and arrogance

6/8/2017
More
Bill Anderson on Jan. 1 became CEO of biotech pioneer Genentech Inc. We talked to him as part of our annual Biotech Forum about issues ranging from cancer immunotherapy, drug pricing and lessons learned at Genentech since 2006.

Duration:00:26:00

The cancer fighter, the Probody and the biotech boom

6/6/2017
More
CytomX Therapeutics CEO Sean McCarthy talks about the young, growing company's work with "Probodies," its potential $5 billion deal with Bristol-Myers Squibb and what its new space allows it to do.

Duration:00:25:56

Beyond Angelina Jolie: Tracking down the cancer-causing BRCA gene mutation

5/22/2017
More
NetSuite founder Evan Goldberg's personal journey with mutant, cancer-causing BRCA genes led to the seeding a year ago of the BRCA Foundation, aimed at helping people get tested and pushing scientists toward new findings.

Duration:00:26:10

How blown bike tires led to new hope for women with mastectomies

5/4/2017
More
AirXpanders developed and is selling a device that uses carbon dioxide — think bike tire inflators — to expand tissue in preparation for breast reconstruction surgery. Listen to how it came to be and where the Palo Alto company is going.

Duration:00:23:20

How a Maverick wants to track down, defeat hard-to-treat cancers

4/12/2017
More
Jeanmarie Guenot, the coofounder of Maverick Therapeutics, talks about her company's novel way of attacking cancer by engaging the body's own T cells.

Duration:00:16:14

Ted Love's quest for a new sickle cell disease treatment

3/2/2017
More
The CEO of Global Blood Therapeutics talks about the pain of patients — mainly African Americans — and how his company hopes to reshape the fight against sickle cell disease.

Duration:00:20:29

Wrapping up this year's J.P. Morgan Healthcare Conference

1/13/2017
More
Wrapping up this year's J.P. Morgan Healthcare Conference by San Francisco Business Times

Duration:00:16:23